PEPPER SIGNED

Project "PEPPER" data sheet

The following table provides information about the project.

 Partnership

Take a look of project's partnership.

Map

 Project objective

The company LenioBio is a biotech company that develops and markets a novel, unique and proprietary protein production platform, ALiCE®, which enables protein-based therapeutics to become more accessible and affordable and specifically targeting the substantial but underserved class of ‘difficult-to-express (DTE) proteins’.

LenioBio has developed a proprietary tobacco-based cell-free protein synthesis (CFPS) platform “ALiCE” with a higher yield (3 mg/ml) than any other eukaryotic cell-free system currently available (0.2 mg/ml) at a lower cost, while ensuring protein stability and activity. The goal of PEPPER is to bring LenioBio to a position of competitiveness and growth to be able to meet the current industrial demands of ‘difficult- to-produce’ proteins for various biotechnology sectors (e.g. pharmaceutical, and agricultural industries). To achieve this, LenioBio will scale-up the protein production capacity and yield to be able to produce proteins at an industrial scale using a semi- automated platform, while complying to GMP protocols and FDA/EMA regulations for biopharmaceuticals proteins. LenioBio’s mission is to offer a fully integrated protein production platform for pharmaceutical and biotechnology companies with the ability to scale along with our customers’ needs. LenioBio is developing the ALiCE® technology into the first eukaryotic cell-free production platform for any proteins.

LenioBio launched its first product as a protein expression kit in 2018 under the name ALiCE® (Almost Living Cell-free Expression). Due to its sustainable competitive advantages, already within nine months, 8 of the top 10 biopharma companies are customers, with more in the process of registering LenioBio as a vendor.